

Hemovigilance Module Adverse Reaction Post Transfusion Purpura

*Required for saving *Facility ID#: NHSN Adverse Reaction #: **Patient Information** *Date of Birth: ____/___ *Patient ID: *Sex: M Secondary ID: Social Security #: Medicare #: Middle Name: Last Name: First Name: Not Hispanic or Ethnicity (Specify): Unknown Declined to respond Hispanic or Latino Latino Middle Eastern or North American Indian or Black or African Asian Race (Select all that Alaska Native American apply): Native Hawaiian or White Unknown Declined to respond Pacific Islander Interpreter Needed: Yes No Preferred Language (Specify from the list provided): Unknow Declined to Respond n *Blood Group: $A - \overline{A+}$ O-Blood type not done Transitional ABO / Transitional Transitional ABO / Rh + Transitional ABO / Rh -Group A/Transitional Group B/Transitional Group O/Transitional Rh Group AB/Transitional Rh Rh **Patient Medical History** List the patient's admitting diagnosis. (Use ICD-10 Diagnostic codes/descriptions) Code: _____ Description: Code: _____ Description: _____ Code: Description: List the patient's underlying indication for transfusion. (Use ICD-10 Diagnostic codes/descriptions) Code: _____ Description: ____ Code: _____ Description: _____ Code: Description: **UNKNOWN** List the patient's comorbid conditions at the time of the transfusion related to the adverse reaction. (Use ICD-10 Diagnostic codes/descriptions) NONE Code: _____ Description: Code: _____ Description: Description: Code:

Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)). CDC 57.314 Rev. 3, v9.2

Public reporting burden of this collection of information is estimated to average 20 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering, and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS H21-8, Atlanta, GA 30333, ATTN: PRA (0920-0666).





	lical procedure including past procedures and procedures to be nospital or outpatient stay. (Use ICD-10 Procedure	UNKNOWN NONE
Code:	Description:	
Code:	Description:	
Code:	Description:	
	Description:	
Transfusion History		
Has the patient received a pro-	evious transfusion?	JNKNOWN
	/B RBC Platelet Plasma Cryoprecipitate	Granulocyte
	//UNKNOWN	Grandiocyte
Was the patient's adverse r		
•	bout the transfusion adverse reaction.	
Type of transfusion adverse		TR FNHTR
	PTP TACO TAD TA-GVHD TRALI	UNKNOWN
Reaction Details		
	/ *Time reaction occurred:: Time	e unknown
*Facility location where patien		
Is this reaction associated with a		
Investigation Results		
* Post transfusion purpura	(PTP)	
*Case Definition		
Check all that occurred aft Alloantibodies in the p development of thron	atient directed against HPA or other platelet specific antigen det	tected at or after
Thrombocytopenia (i.e	., decrease in platelets to less than 20% of pre-transfusion cour	nt).
Decrease in platelets t	o levels between 20% and 80% of pre-transfusion count.	
Check all that apply:		
	laboratory findings and/or information are not sufficient. NOTE: latelet count to less than 80% of pre-transfusion count but HPA e.	• •
Other signs and symptoms: (cl	neck all that apply)	
Generalized:	Chills/rigors Fever Nau	usea/vomiting
Cardiovascular:	Blood pressure decrease Shock	
Cutaneous:	Edema Flushing Jau	ndice
	Other rash Pruritus (itching) Urti	caria (hives)
Hemolysis/Hemorrhage:	Disseminated intravascular coagulation Hemoglobin	emia
	Positive antibody screen	
Pain:	Abdominal pain Back pain Flank pain	Infusion site pain
Renal:	Hematuria Hemoglobinuria Olig	guria



Respiratory:	Bronchospasm Cough of breath	
Other: (specify)	Hypoxemia Shortness	51 51 51 51 51 51 51 51 51 51 51 51 51 5
*Severity		
Did the patient receive or ex	perience any of the following?	
No treatment require	ed Symptomatic treati	nent only
	iding prolonged hospitalization	Life-threatening reaction
Disability and/or inca		y or birth defect(s) of the fetus
Other medically impo		Unknown or not stated
*Imputability		
· · · · · · · · · · · · · · · · · · ·	lationship between the transfusion and the re	action?
	conditions to explain thrombocytopenia.	
There are other poten likely cause.	ntial causes present that could explain thromb	pocytopenia, but transfusion is the most
	s for thrombocytopenia are more likely, but tr	ansfusion cannot be ruled out.
	favor of a cause other than the transfusion, b	
There is conclusive ev	vidence beyond reasonable doubt of a cause	other than the transfusion.
The relationship betwe	een the adverse reaction and the transfusion	is unknown or not stated.
Did the transfusion occur at	vour facility? YES NO	
	in relation to the transfusion?	
Occurred less than 5	or more than 12 days post-transfusion	
Module-generated Designa		
	finition, severity, and imputability will be auto	 matically assigned in the NHSN
<u> </u>	in the corresponding investigation results sed	
*Do you agree with the <u>ca</u>	<u>se <i>definition</i></u> designation?	YES NO
^Please indicate your desig	nation	
*Do you agree with the <u>se</u> ^Please indicate your desig		YES NO
*Do you agree with the <u>im</u>	putability designation?	YES NO
^Please indicate your desig		
Patient Treatment		
Did the patient receive treatme	ent for the transfusion reaction? \Box	YES NO UNKNOWN
If yes, select treatment(s):		
Medication (Select the	e type of medication)	
A	Antibiatamina Instrument (Company)	Duanaha dilatan Diserati sa
Antipyretics	Antihistamines Inotropes/Vasopressors	Bronchodilator Diuretics
Intravenous Immunoglobulin	Intravenous steroids	Corticosteroids Antibiotics
Antithymocyte gl		7.11.101.000



Form Approved OMB No. 0920-0666 Exp. Date: 12/31/2027

SAFETY NETY VOIL	work ime resuscitation (Inti	ravenous colloid	ls or crystalloids)		www.	cdc.gov/nhsn
Res	piratory support <i>(Sele</i>		<i>upport)</i> nvasive ventilatior	n Oxyger	n	
Ren	al replacement therap	oy (Select the ty Peritoneal		no-Venous Hem	nofiltration	
Phle Othe	ebotomy er Specify:					
Outcome						
*Outcome: Date of		lajor or long-terr /	m sequelae se	Minor or no equelae	Not determ	mined
Cause	recipient died, relation Definite Probabl of death:	. —	le Doubtful	Ruled Ou	ut Not determine	ed
Was an	autopsy performed?	Yes	No			
Component	Details					
*Was a partion?	cular unit implicated	d in (i.e., respo		adverse	Yes No	N/A
Transfusion Start and End Date/Time	*Component code (check system used)	Amount transfused at reaction onset	^Unit number (Required for Infection and TRALI)	*Unit expiration Date/Time	*Blood group of unit	Implicate d Unit?
^IMPLICATED	UNIT					
	ISBT-128 Codabar	Entire unit		, ,	A- A+ B-	
		Partial unitmL		:	B+ AB- AB+ O- O+ N/A	Y
	ISBT-128 Codabar			: 	B+ AB- AB+	Y N
//	Codabar — — —	Entire unit Partial unit		:	B+ AB- AB+ AB- AB+ AB- AB+ AB- AB+	
	Codabar — — —	Entire unit Partial unit	Label	:	B+ AB- AB+ AB- AB+ AB- AB+ AB- AB+	
	Codabar — — —	Entire unit Partial unit	Label	:	B+ AB- AB+ AB- AB+ AB- AB+ AB- AB+	



Form Approved OMB No. 0920-0666 Exp. Date: 12/31/0207

www.cdc.gov/nhsn